A novel risk-stratification index can help avoid unnecessary colonoscopies in individuals at low-risk for developing colorectal cancer.
Researchers have developed a risk-stratification index that will stratify patients who have an average risk of developing colorectal cancer (CRC). This system would enable tailoring of screening within this group, with less invasive tests (sigmoidoscopy or occult blood tests) for lower-risk persons and colonoscopy for higher-risk persons. The researchers believe this could improve the uptake of CRC screening, which is currently underutilized but recommended for those over 50 years of age.
This cross-sectional study, published in the Annals of Internal Medicine, included persons between 50 and 80 years of age who were undergoing initial colonoscopy in endoscopy units across the Midwestern regions of the country. The study period was December 2004 to September 2011.
Of the 4460 patients included in the study, 2993 were included in the derivation set and 1467 in the validation set. A clinical score was given based on the patient's complete health data and points from regression coefficients for age, sex, waist circumference, cigarette smoking, and family history. Of those in the derivation set, 9.4% had advanced neoplasia; risks for advanced neoplasia in individuals at very low, low, intermediate, and high risk were 1.92%, 4.88%, 9.93%, and 24.9%, respectively. Sigmoidoscopy to the descending colon in the low risk group would have detected 73% of advanced neoplams, the authors report. In the validation set, the corresponding risks for advanced neoplasias were 1.65%, 3.31%, 10,9%, and 22.3%, and sigmoidoscopy would have detected 87.5% of advanced neoplams.
The authors conclude that their risk stratification score identifies the lower-risk group among whom noncolonoscopy screening strategies can be effective and efficient. While avoiding patient discomfort, the risk-estimating index can also reduce healthcare costs associated with unnecessary screening colonoscopies, which also speaks to the aims of the Choosing Wisely initiative.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More